前列腺癌术后个体化治疗:I/II期试验最终结果
这项I/II期试验纳入123例根治性前列腺切除术后具高危病理特征的患者,给予调强放疗联合激素治疗等个体化辅助治疗,中位随访67个月,5年生化无病生存率达92.9%,高于标准辅助放疗的历史对照。
要点
- 术后个体化辅助治疗5年bDFS达92.9%,优于EORTC 22911的74%。
- 所有患者接受瘤床至少64.8 Gy放疗,多数联合激素治疗。
- 长期无病生存与总生存仍需进一步评估。
核心结论
- 术后个体化联合强化辅助治疗使5年生化无病生存率达92.9%,高于标准辅助放疗的历史研究。
研究设计与样本
- I/II期试验连续纳入123例根治性前列腺切除术后患者,年龄<80岁,pT2-4N0-1,ECOG 0-2,且至少具一项高危病理特征。
主要发现
- 中位随访67个月(范围37-120个月),5年实际生化无病生存率92.9%,局部控制率98.7%,无转移生存率96.1%,总生存率95.1%。
- 术前和术后中位PSA分别为8.8和0.06 ng/mL,病理淋巴结阳性率14.6%,切缘阳性率58.5%。
关键数值与推荐
- 所有患者瘤床放疗至少64.8 Gy,85.4%接受70.2 Gy,57.7%接受预防性盆腔淋巴结照射,69.1%接受激素治疗。
- 生化复发定义为连续两次PSA升高且>0.2 ng/ml。
临床怎么用
- 对根治性前列腺切除术后具高危病理特征的患者,可考虑个体化强化辅助放疗联合激素治疗以改善生化控制。
局限性
- 为I/II期单臂试验,无同期对照,长期无病生存和总生存需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUD: The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes by using a combined-intensified-modulated-adjuvant treatment, including RT and hormone therapy (HT) after RP. MATERIALS AND METHODS: This phase I/II trial treatment was designed to improve 5-year bDFS from ~ 75 to 90%. Patients were consecutively enrolled using the following inclusion criteria: age < 80 years, histological diagnosis of prostate adenocarcinoma without known metastases, stage pT2-4N0-1, and Eastern Cooperative Oncology Group performance status of 0-2. All patients had at least one of these pathologic features: capsular perforation, positive surgical margins, seminal vesicle invasion, and pelvic lymph nodes involvement. A minimum dose of 64.8 Gy to the tumor bed was delivered in all patients. Depending on tumor characteristics at diagnosis, patients received a higher dose (70.2 Gy; 85.4%) and/or prophylactic pelvic lymph nodes irradiation (57.7%) and/or HT (69.1%). Biochemical relapse was defined as two consecutive rising prostate-specific antigen (PSA) values > 0.2 ng/ml. RESULTS: A total of 123 patients were enrolled in the study and completed the scheduled treatment. Median preoperative and postoperative PSA were: 8.8 and 0.06 ng/mL, respectively. The percentages of patients with pathologically involved nodes and positive resection margins were: 14.6% and 58.5%, respectively. With a median follow-up of 67 months (range: 37-120 months), the actuarial 5-year bDFS, local control, metastasis-free survival, and overall survival (OS) were: 92.9%, 98.7%, 96.1%, and 95.1%, respectively. CONCLUSION: A higher 5-year bDFS (92.9%) was recorded compared to studies based on standard adjuvant RT, even though patients with nodal disease and detectable postoperative PSA were enrolled. Clinical end points, as long-term disease-free survival and OS, will require further assessments. (ClinicalTrials.gov: NCT03169933).
引用
- Mantini G, Siepe G, Alitto AR, et al. Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial. Prostate Cancer Prostatic Dis. 2018. PMID: 30038390. doi:10.1038/s41391-018-0064-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。